Virpax Pharmaceuticals (NASDAQ:VRPX) (NASDAQ: VRPX) is a specialty pharmaceutical company focused on the development, commercialization and licensing of both branded and generic prescription drugs. The company’s operations center on acquiring, developing and launching solid oral dose products, with an emphasis on analgesics and other high-demand therapeutic categories. Virpax combines in-house formulation expertise with strategic partnerships to advance approved products and pipeline candidates through regulatory review and market introduction.
The Virpax portfolio includes a range of orally administered medications, including immediate-release and extended-release formulations of opioid and non-opioid analgesics. Through a combination of internally filed ANDAs (Abbreviated New Drug Applications) and licensed product rights, the company has built a commercial suite that addresses pain management needs in both acute and chronic settings. Virpax works closely with contract manufacturing organizations and third-party distributors to ensure product availability across retail and institutional channels.
Headquartered in Fort Lauderdale, Florida, Virpax serves patients and healthcare providers throughout the United States. The company’s commercial infrastructure spans national wholesalers, specialty pharmacies and hospital networks, while business development efforts target complementary therapeutic areas and new market segments. Since completing its business combination and listing on the Nasdaq exchange in early 2021, Virpax has pursued a disciplined growth strategy, focusing on timely product launches and ongoing pipeline expansion.
Under the leadership of President and Chief Executive Officer Michael I. P. Grey, Virpax Pharmaceuticals emphasizes operational efficiency, regulatory compliance and strategic licensing arrangements. The management team brings experience from established pharmaceutical firms and contract development and manufacturing organizations, guiding the company’s efforts from initial product concept through post-market support. With a foundation built on a specialized product lineup and targeted commercial execution, Virpax aims to deliver consistent value to patients, partners and shareholders.
